Human VCAM-1/CD106 Antibody

Detection of Human VCAM‑1/CD106 by Western Blot.

Western blot shows lysates of 786-O human renal cell adenocarcinoma cell line. PVDF membrane was probed with 2 µg/mL of Sheep Anti-Human VCAM-1/ CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for VCAM-1/CD106 at approximately 100 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Human VCAM-1/CD106 by Simple Western^TM.

Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells untreated (-) or treated (+) with 10 ng/ml Recombinant Human TNF-alpha (210-TA) for 24 hrs, loaded at 0.2 mg/mL. A specific band was detected for VCAM-1/CD106 at approximately 132 kDa (as indicated) using 20 µg/mL of Sheep Anti-Human VCAM-1/CD106 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF809) followed by 1:50 dilution of HRP-conjugated Anti-Sheep IgG Secondary Antibody (HAF016). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Mouse VCAM-1/CD106 by Flow Cytometry

Inhibition of ICAM-1- and VCAM-1-mediated cell adhesion reduces T-ALL burden in vivo. A Experimental schematic depicting dosing schedule for anti-ICAM-1, anti-VCAM-1, or isotype control antibodies following establishment of LN3 T-ALL ( > 1% spleen chimerism) in congenic hosts. Leukemia burden was assessed 2 days after the final antibody injection. b Quantification of spleen and liver weights from the experiments depicted in (a). Tumor-free, age-matched mice were included for comparison. Bars depict the mean + SEM of cumulative data from n = 5 experiments, each with a distinct color-coded primary T-ALL; symbols represent individual mice. c Representative flow cytometry plots showing a decrease in T-ALL burden in the spleens of LN3 T-ALL-transplanted mice following treatment with anti-ICAM-1 +/- anti-VCAM-1 antibodies (100 µg each per mouse). d, e Quantification of the (d) frequency of circulating T-ALL blasts in the blood and (e) number of T-ALL cells in the spleen, BM, LN, and liver from the same experiments as in (b). f Quantification of the indicated myeloid subsets or TCR beta+ or B220+ host cells in the spleens of mice from the same experiments as in (d, e). Statistical significance was determined by (b, d, e, f) a two-sided repeated measures one-way ANOVA with the Holm-Sidak correction; P-values: *<0.05, **<0.01, ***<0.001. ns, not significant. Source data are provided as a Source Data file. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37805579), licensed under a CC-BY license. Not internally tested by R&D Systems.